VON In-Person Meeting
Subject matter experts who have direct experience and expertise in the following are presenting:
- Newly approved oncology medications and emerging drug therapies
- Implementation of a system-wide virtual pharmacist second-check verification
- Panel discussion: CAR T use in the ambulatory setting; strategies to increase workforce retention; healthcare landscape for payer trends and site of care challenges
Faculty and members with subject matter expertise will present information and guide discussion with a focus on how the attendees can use the information to implement it in their setting, including key takeaway points with each presentation. The audience will be engaged in discussion and can ask questions verbally to further their knowledge and confidence.
Pharmacists learning objectives:
At the conclusion of this activity, pharmacists should be able to:
- Describe a basic understanding of their mechanism of action.
- Identify the medications potential to be included in the current standards of care.
- Translate how the medication will be incorporated into the current clinical treatment options.
System-wide Virtual Pharmacist Second-Check Chemotherapy Verification
- Review the data supporting pharmacist remote verifications
- Develop a procedure for completing a remote pharmacist chemotherapy verifications.
Hot Topics in Oncology Pharmacy
- Describe tactics that can be implemented to retain pharmacist and technician workforce.
- Outline criteria for successful management of CAR-T in the ambulatory setting.
- Recognize opportunities for the health-system to address site of care challenges.
Carina Dolan, PharmD, MS Pharm, BCOP
Sr Director for Clinical Oncology and Pharmaceutical Outcomes
Pharmacy Solutions, Center for Pharmacy Practice Excellence
Megan Mullalley, PharmD, BCOP, BCPS
System Oncology Pharmacy Manager
Scott Freeswick, MS, PharmD
Vice President/Chief Pharmacy Officer
Memorial Sloan Kettering Cancer Center
Sylvia Bartel, RPH, MHP
Dana Farber Cancer Institute
Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
Associate Director, James Cancer Hospital Clinical Services
The Ohio State University – The James Cancer Hospital
Travis Hunerdosse, PharmD, MBA
Senior Director, Pharmacy Networks
Pei Jen Lin, PharmD, MS, BCPS
Lead Project Manager, Pharmacy Networks
Disclosure of Financial Relationships:
Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
Scott Freeswick, MS, PharmD, speaker for this educational activity, is an advisor for Fresenius Kabi and Exelixis.
All relevant financial relationships listed for these individual(s) have been mitigated.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 2.00 ACPE credit hours.
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 2.00 ACPE Pharmacist
- 2.00 General CE – Attendance